Department of Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Batterjee Medical College for Sciences and Technology, Jeddah, Saudi Arabia.
Pathol Oncol Res. 2020 Apr;26(2):1313-1318. doi: 10.1007/s12253-019-00704-2. Epub 2019 Aug 1.
CD10 and inhibin are used mainly in CNS pathology to distinguish hemangioblastoma from metastatic clear cell renal cell carcinoma. Some meningiomas can mimic both tumors and so we aimed at this study to investigate the expression of both markers in a large number of meningioma cases. One hundred thirty-four meningioma samples were collected, 14 of them were spinal and 120 were intracranial. Manual TMA blocks were constructed using modified mechanical pencil tip method and immunohistochemistry for CD10 and inhibin was done. Intracranial meningioma occurred in significantly younger age than spinal ones. Most of spinal meningiomas were of transitional histology. CD10 was expressed in 14% of cases with significant positivity in spinal rather than intracranial cases. Transitional meningiomas showed the highest positivity for CD10 expression, while the least positive was the meningiotheliomatous type. Inhibin was expressed in 6% of cases with no significant relation to clinicopathological and histological features. There was no significant relationship between the expression of CD10 and inhibin expression in meningiomas. In conclusion, spinal meningiomas differ than intracranial ones in many clinicopathological and biological aspects. Among these differences is CD10 expression being more expressed in spinal meningiomas. However CD10 and inhibin are aberrantly expressed in a proportion of meningiomas, both have no relations to poor prognostic factors but more caution should be exerted during usage of these markers in diagnosis of hemangioblastoma and metastatic RCC. Further studies are suggested for exploring more biological differences between spinal and intracranial meningiomas.
CD10 和抑制素主要用于中枢神经系统病理学，以区分血管母细胞瘤与转移性透明细胞肾细胞癌。一些脑膜瘤可以模拟这两种肿瘤，因此我们旨在这项研究中调查大量脑膜瘤病例中这两种标志物的表达。收集了 134 例脑膜瘤样本，其中 14 例为脊髓，120 例为颅内。使用改良的机械铅笔尖方法构建手动 TMA 块，并进行 CD10 和抑制素的免疫组织化学染色。颅内脑膜瘤的发病年龄明显低于脊髓脑膜瘤。大多数脊髓脑膜瘤为过渡性组织学。CD10 在 14%的病例中表达，脊髓病例的阳性率明显高于颅内病例。过渡性脑膜瘤的 CD10 表达阳性率最高，而脑膜内皮细胞瘤型的阳性率最低。抑制素在 6%的病例中表达，与临床病理和组织学特征无显著关系。脑膜瘤中 CD10 和抑制素表达之间没有显著关系。总之，脊髓脑膜瘤在许多临床病理和生物学方面与颅内脑膜瘤不同。这些差异之一是 CD10 在脊髓脑膜瘤中表达更为明显。然而，CD10 和抑制素在一部分脑膜瘤中异常表达，它们与不良预后因素无关，但在诊断血管母细胞瘤和转移性 RCC 时应更加谨慎地使用这些标志物。建议进一步研究探索脊髓和颅内脑膜瘤之间更多的生物学差异。
